USPTO serial 79275472
ACAZEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 26, 2021
- Examiner
- EISNACH, MICHAEL PATRICK
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ACAZEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Alpinia Institute for Life Sciences AG
CH
Other trademarks owned by Alpinia Institute for Life Sciences AG
Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG
CH
Other trademarks owned by Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG
Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG
CH
Other trademarks owned by Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Frank W. Compagni
Frank W. Compagni Morriss O'Bryant Compagni Cannon, PLLC4505 S Wasatch Blvd, Suite 270Salt Lake City, UT 84124UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutritional supplements for medical use; medicines, particularly phytopharmaceutical products, namely, pharmaceutical preparations for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); active plant agents and plant extracts for medical use, namely, plant extracts for pharmaceutical purposes; pharmaceutical, veterinary and sanitary products, namely, pharmaceutical preparations for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); dietetic substances in the nature of food and beverages for medical use, food for babies; adjuvants for medical use; amino acids for medical use; anesthetics; analgesics; vermifuges; antibiotics; biological preparations for medical use, namely, biological preparations for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); chemical products for medical use, namely, chemical preparations for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); chemical reagents for medical or veterinary use; chemico-pharmaceutical products, namely, chemical-pharmaceutical preparations for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); ferments for pharmaceutical use; hormones for medical use; medical infusions for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); medicines for dental use, namely, medicines for treating dentalirritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); medicines for human medicine, namely, pharmaceutical preparations for treating irritable bowel syndrome, constipation, diarrhoea, inflammatory bowel disease, coeliac disease, intolerance to FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols); radiological contrast substances for medical use; steroids | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alpinia Institute for Life Sciences AG
- Other trademarks owned by Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG
- Other trademarks owned by Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG
- Other trademarks in Class 005
- Similar marks named ACAZEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 4, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 26, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 7, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 15, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 30, 2021 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Apr 29, 2021 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Apr 26, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 26, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 10, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 10, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 8, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 21, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 21, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 21, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 6, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 6, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 6, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 6, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 6, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 25, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 24, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 24, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 10, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 24, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 24, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 4, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 3, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 14, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 8, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 2, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |